Three observational studies compared VTE risk between SGLT2 inhibitors and DPP-4 inhibitors in T2DM patients.51, 52, 53Schmedt et al.51used a nested case–control design to include 2,152 VTE cases and 85,104 matched controls, finding that SGLT2 inhibitors were associated with a lower VTE risk compared with DPP-4 inhibitors (RR 0.75, 95% CI 0.59–0.94, though the estimate may actually represent OR based on the described methodology). Here, DPP4 is linked to type 2 diabetes mellitus.